Vitex agnus-castus в терапии предменструального синдрома: анализ данных за 30 лет

1. Modzelewski S., Oracz A., Żukow X., Iłendo K., Śledzikowka Z., Waszkiewicz N. Premenstrual syndrome: new insights into etiology and review of treatment methods. Front. Psychiatry. 2024; 15: 1363875. https://dx.doi.org/10.3389/fpsyt.2024.1363875
2. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Предменструальный синдром. 2024.
3. Green L.J., O’Brien P.M.S., Panay N., Craig M. on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. BJOG. 2017; 124: e73-e105. https://dx.doi.org/10.1111/1471-0528.14260
4. Shaw S., Wyatt K., Campbell J., Ernst E., Thompson‐Coon J. Vitex agnus castus for premenstrual syndrome. Cochrane Database Syst. Rev. 2018; 2018(3): CD004632. https://dx.doi.org/10.1002/14651858.CD004632.pub2
5. Sirotkin A.V. Effects, mechanisms of action and application of vitex agnus-castus for improvement of health and female reproduction. Phytother. Res. 2025; 39(3): 1484-93. https://dx.doi.org/10.1002/ptr.8438
6. Höller M., Steindl H., Abramov-Sommariva D., Kleemann J., Loleit A., Abels C. et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch. Gynecol. Obstet. 2024; 309(5): 2089-98. https://dx.doi.org/10.1007/s00404-023-07363-4
7. Уварова Е.В. Эффективность и безопасность применения растительного лекарственного препарата Циклодинон® для лечения нарушений менструального цикла у девочек-подростков: обзор опыта клинического применения. Репродуктивное здоровье детей и подростков. 2021; 17(2): 51-64. https://dx.doi.org/10.33029/1816-2134-2020-17-2-51-64
8. Ледина А.В., Прилепская В.Н. Предменструальный синдром: возможности дифференцированного подхода к лечению. Акушерство и гинекология. 2018; 11: 92-7. https://dx.doi.org/10.18565/aig.2018.11.92-97
9. Мальцева О.И. Роль гиперпролактинемии в генезе преждевременного телархе и ее коррекция у девочек первых пяти лет жизни. Здоровье женщины. 2016; 4(110): 160.
10. Артымук Н.В., Зотова О.А. Влияние препарата «Циклодинон» на сексуальную функцию у пациенток с бесплодием и нарушениями менструального цикла. Акушерство и гинекология. 2023; 11: 158-68. https://dx.doi.org/10.18565/aig.2023.193
11. Мардонова С.М., Абдуллоходжаева Г.А., Абдулазизова Ф. Негормональная терапия нарушений менструального цикла в ювенильном возрасте. Наука и инновация. 2016; 4(12): 8-15.
12. Татарчук Т.Ф., Косей Н.В., Регеда С.И., Яроцкая Н.В., Горохова А.А. Гиперпролактинемия в генезе стресс-индуцированного бесплодия. Возможности фитотерапии. Здоровье женщины. 2017; 3(119): 28.
13. Сулейманова Н.Д., Мухамметкулиева О.С. Оценка фармакологической эффективности циклодинона в лечении предменструального синдрома у подростков, проживающих в жарком климате. Медицина: теория и практика. 2019; 4(S): 532-3.
14. Адамов Г.В., Мельников Е.С., Лупанова И.А. Радимич А.И., Сайбель О.Л. Изучение химического состава и дофаминергической активности плодов Витекса священного (Vitex agnus-castus L.). Разработка и регистрация лекарственных средств. 2020; 9(3): 143-9. https://dx.doi.org/10.33380/2305-2066-2020-9-3-143-149
15. Rethlefsen M.L., Kirtley S., Waffenschmidt S., Ayala A.P., Moher D., Page M.J. et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst. Rev. 2021; 10(1): 39. https://dx.doi.org/10.1186/s13643-020-01542-z
16. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev. Esp. Cardiol. (Engl. Ed.). 2021; 74(9):790-9. English, Spanish. https://dx.doi.org/10.1016/j.rec.2021.07.010. Erratum in: Rev. Esp. Cardiol. (Engl. Ed.). 2022; 75(2): 192. https://dx.doi.org/10.1016/j.rec.2021.10.019
17. Lauritzen C., Reuter H.D., Repges R., Böhnert K.J., Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine. Phytomedicine. 1997; 4(3): 183-9. https://dx.doi.org/10.1016/S0944-7113(97)80066-9
18. Daniele C., Thompson Coon J., Pittler M.H., Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005; 28(4): 319-32. https://dx.doi.org/10.2165/00002018-200528040-00004
19. Dante G., Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J. Psychosom. Obstet. Gynaecol. 2011; 32(1): 42-51. https://dx.doi.org/10.3109/0167482X.2010.538102
20. van Die M.D., Burger H.G., Teede H.J., Bone K.M. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013; 79(7): 562-75. https://dx.doi.org/10.1055/s-0032-1327831
21. Jang S.H., Kim D.I., Choi M.S. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome / premenstrual dysphoric disorder: systematic review. BMC Complement Altern Med. 2014; 14: 11. https://dx.doi.org/10.1186/1472-6882-14-11
22. Cerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health. 2017; 20(6): 713-19. https://dx.doi.org/10.1007/s00737-017-0791-0
23. Rafieian-Kopaei M., Movahedi M. Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus castus. Electron. Physician. 2017; 9(1): 3685-9. https://dx.doi.org/10.19082/3685
24. Verkaik S., Kamperman A.M., van Westrhenen R., Schulte P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017; 217(2): 150-66. https://dx.doi.org/10.1016/j.ajog.2017.02.028
25. Maleki-Saghooni N., Karimi F.Z., Behboodi Moghadam Z., Mirzaii Najmabadi K. The effectiveness and safety of Iranian herbal medicines for treatment of premenstrual syndrome: a systematic review. Avicenna J. Phytomed. 2018; 8(2): 96-113.
26. Csupor D., Lantos T., Hegyi P., Benkő R., Viola R., Gyöngyi Z. et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. Complement. Ther. Med. 2019; 47(17): 102190. https://dx.doi.org/10.1016/j.ctim.2019.08.024
27. Ooi S.L., Watts S., McClean R., Pak S.C. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. J. Womens Health (Larchmt). 2020; 29(2): 262-78. https://dx.doi.org/10.1089/jwh.2019.7770
28. Halaska M., Raus K., Beles P., Martan A., Paithner K.G. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol. 1998; 63(5): 388-92.
29. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001; 322(7279): 134-7. https://dx.doi.org/10.1136/bmj.322.7279.134
30. Atmaca M., Kumru S., Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003; 18(3): 191-5. https://dx.doi.org/10.1002/hup.470
31. He Z., Chen R., Zhou Y., Geng L., Zhang Z., Chen S. et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009; 63(1): 99-103. https://dx.doi.org/10.1016/j.maturitas.2009.01.006
32. Ma L., Lin S., Chen R., Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol. Endocrinol. 2010; 26(8): 612-6. https://dx.doi.org/10.3109/09513591003632126
33. Ma L., Lin S., Chen R., Zhang Y., Chen F., Wang X. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust. NZ J. Obstet. Gynaecol. 2010; 50(2): 189-93. https://dx.doi.org/10.1111/j.1479-828X.2010.01137.x
34. Schellenberg R., Zimmermann C., Drewe J., Hoexter G., Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012; 19(14): 1325-31. https://dx.doi.org/10.1016/j.phymed.2012.08.006
35. Zamani M., Neghab N., Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med. Iran. 2012; 50(2): 101-6.
36. Herrera A., Al Adib M., Rodríguez A.B., Carrasco C. Effects of the PREMEN-CALM® in the management of the premenstrual syndrome: a randomized, double-blind, placebo-controlled pilot study. J. Diet. Suppl. 2024; 21(4): 495-511. https://dx.doi.org/10.1080/19390211.2023.2301398
37. Partovi Golshan R., Moradi M., Rakhshandeh H., Ghavami V., Moshirian Farahi S.M. Comparison of the effects of vitagnus, soy, and vitagnus-soy capsules on premenstrual syndrome in university students: a randomized clinical trial. Int. J. Community Based Nurs. Midwifery. 2025; 13(1): 2-15. https://dx.doi.org/10.30476/ijcbnm.2024.102930.2543
38. Mirzaee F., Fakari F.R., Babakhanian M., Roozbeh N., Ghazanfarpour M. The effectiveness of herbal medicines on cyclic mastalgia: a systematic review on meta-analysis. Rev. Bras. Ginecol. Obstet. 2022; 44(10): 972-85. https://dx.doi.org/10.1055/s-0042-1755456
39. Heirati S.F.D., Ozgoli G., KabodMehri R., Mojab F., Sahranavard S., Nasiri M. The 4-month effect of Vitex agnus-castus plant on sexual function of women of reproductive age: a clinical trial. J. Educ. Health Promot. 2021; 10: 294. https://dx.doi.org/10.4103/jehp.jehp_63_21
40. Puglia L.T., Lowry J., Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Front. Endocrinol. (Lausanne). 2023; 14: 1269781. https://dx.doi.org/10.3389/fendo.2023.1269781
41. Soleimany Z., Siadat F., Farhadi M., Mirshaby Z.S., Sanadgol Z., Eyni H. Improvement of ovarian function in a premature ovarian failure mouse model using Vitex agnus-castus extract. JBRA Assist. Reprod. 2025; 29(1): 117-26. https://dx.doi.org/10.5935/1518-0557.20240101
42. Ishaq S., H Rizwani G., Shareef H., Fatima S., Anser H., Sarfraz S. A herbal treatment approach for the management of clinical, hormonal and ultrasound parameters in reproductive age group women with polycystic ovarian syndrome: a randomized clinical trial. Pak. J. Pharm. Sci. 2021; 34(3S): 1097-102.
43. Hameed L., Farooq A.D., Qureshi T. Analysis of Unani coded formulation on the hormonal parameters of patients with polycystic ovarian syndrome. Pak. J. Pharm. Sci. 2021; 34(3): 899-907.
44. Hatami A., Seidi F., Khosrowbeygi A., Moslemi A., Jalali-Mashayekhi F. The effect of Vitex agnus-castus plant on some markers of oxidative stress, lipid profile and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind controlled clinical trial study. JBRA Assist. Reprod. 2026; 30(1): 70-8. https://dx.doi.org/10.5935/1518-0557.20250165
45. Tumsutti P., Maiprasert M., Sugkraroek P., Wanitphakdeedecha R., Bumrungpert A. Effects of a combination of botanical actives on skin health and antioxidant status in post-menopausal women: a randomized, double-blind, placebo-controlled clinical trial. J. Cosmet. Dermatol. 2022; 21(5): 2064-72. https://dx.doi.org/10.1111/jocd.14345
46. Sopjani M., Murati V., Mataj-Berisha D., Xuan N.T., Faggio C., Rifati-Nixha A. Vitex agnus-castus in menopause: phytochemistry, mechanistic insights, clinical applications, and safety perspectives. Phytother. Res. 2026; 40(4): 1919-34. https://dx.doi.org/10.1002/ptr.70237
47. Management of premenstrual disorders: ACOG Clinical Practice Guideline No. 7. Obstet. Gynecol. 2023; 142(6): 1516-33. https://dx.doi.org/10.1097/AOG.0000000000005426
48. Mishra S., Elliott H., Marwaha R. Premenstrual dysphoric disorder. 2023 Feb 19. In: StatPearls
49. Modzelewski S., Oracz A., Żukow X., Iłendo K., Śledzikowka Z., Waszkiewicz N. Premenstrual syndrome: new insights into etiology and review of treatment methods. Front. Psychiatry. 2024; 15: 1363875. https://dx.doi.org/10.3389/fpsyt.2024.1363875
50. Bitzer J., Bouchard C., Zatik J., Weyers S., Piltonen T., Suturina L. et al. Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia. Eur. J. Contracept. Reprod. Health Care. 2024; 29(1): 1-10. https://dx.doi.org/10.1080/13625187.2024.2359117
51. Berni L.C., Nunes L.R., Oliveira R.C.S. Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis. J. Psychiatr. Res. 2026; 194: 99-115. https://dx.doi.org/10.1016/j.jpsychires.2025.12.046
52. Сухих Г.Т., Серов В.Н., Подзолкова Н.М., Баранов И.И., Андреева М.Д., Артымук Н.В., Беженарь В.Ф., Долгушина Н.В., Дубровина С.О., Енькова Е.В., Габидуллина Р.И., Каткова Н.Ю., Коган И.Ю., Коренная В.В., Кукарская И.И., Макаренко Т.А., Молчанова И.В., Назаренко Т.А., Оленев А.С., Савельева И.В., Семенов Ю.А., Сметник А.А., Спиридонова Н.В., Тапильская Н.И., Тетруашвили Н.К., Уварова Е.В., Фадеев В.В., Ших Е.В., Ярмолинская М.И. Сохранение репродуктивного здоровья как основа повышения рождаемости. Совместная позиция экспертов в области репродуктивной медицины, акушерства, гинекологии, эндокринологии и клинической фармакологии. Акушерство и гинекология. 2025; 10: 180-92. https://dx.doi.org/10.18565/aig.2025.265
53. Qiang R., Guo L., Xu Z., Gu Y., Liu Y., Wang Y. et al. Global, regional, and national burden of premenstrual syndrome from 1990 to 2021 and projections to 2050: an analysis based on the 2021 global burden of disease study. Front. Psychiatry. 2025; 16: 1644774. https://dx.doi.org/10.3389/fpsyt.2025.1644774
54. Gu D., Qi M., Gui R., Zhou D., Su C., Hu P. et al. Global burden of non-neoplastic gynecological diseases in females: a 32-year analysis with projections to 2100. Am. J. Prev. Med. 2025; 71(1): 108099. https://dx.doi.org/10.1016/j.amepre.2025.108099

Поступила 30.04.2026

Принята в печать 02.06.2026